Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?

被引：0
|
作者：
Arthur Kavanaugh
机构：
[1] Allergy,Professor of Medicine and the Director of the Center for Innovative Therapy in the Division of Rheumatology
[2] and Immunology at the University of California San Diego,undefined
来源：
Nature Clinical Practice Rheumatology | 2006年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tumor necrosis factor (TNF) inhibitors have proven highly effective in improving the signs and symptoms of rheumatoid arthritis, in inhibiting the progression of joint damage, and improving patients' quality of life. This Viewpoint will discuss the major concern relating to the actual use of TNF inhibitors in the clinic: their relatively high acquisition costs.
引用
收藏
页码：346 / 347
页数：1
相关论文
共 50 条
12345